Kepler Capital Sticks to Its Buy Rating for Merck KGaA (0O14)
In a report released on November 14, David Evans from Kepler Capital maintained a Buy rating on Merck KGaA (0O14 – Research Report), ...
GlobalData on MSN14h
FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria
The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.
Regeneron, Sanofi announce FDA accepts Dupixent sBLA for review
Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for review the resubmission of the supplemental Biologics License ...
Scientists fear what’s next for public health if RFK Jr. is allowed to ‘go wild’
Should Kennedy win Senate confirmation, his critics say he is threatening the achievements of a science-based public health ...
Regeneron, Sanofi Get New FDA Review of Dupixent for CSU
The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...